The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study
Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng · 2025
Read The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study by Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12723850.txt.
Description
Xinrong Li and nine co-authors test if daratumumab, a myeloma drug, cuts bone breaks and like harms in new patients. Their study appeared in twenty twenty-five. The drug hits a mark on tumor cells and works well, but its bone role was thinly known. Past cases of more than one hundred sixty new patients from many hubs were weighed, some on the drug and some not.
Bone harms hit near one fifth in all, less in the drug group but not by a firm span. In folks with sound blood calcium at start, the drug cut harm risk by a lot. A like edge showed in mid-risk folks. The team calls for more proof of a bone guard role.
Catalog record
| CREATOR | Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |